[The cardioprotective action of 18-dehydroglycyrrhetic acid in experimental myocardial damage].
Experiments on rats with isadrine damage to the myocardium showed that when used for preventive-therapeutic purposes 18-dehydroglycyrrhizic acid (glyderinine preparation) causes statistically significant prevention of a rise in the serum level of marker enzymes (creatine phosphokinase, lactate dehydrogenase, aspartate aminotranspherase), prevents activation of lipid peroxidation, decrease of blood serum antioxidation activity and pathological changes in the content of glycogen and total lipids in the heart, it also improves the electrocardiographic parameters, reduces myocardial inflammatory edema. The results of the study show that glyderinine possesses a marked cardioprotective effect.
Zakirov
N U
NU
Laboratory of Pathophysiology and Experimental Pharmacotherapy, Uzbekistan Ministry of Public Health, Tashkent.
Aĭzimov
M I
MI
Kurmukov
A G
AG
D000318:Adrenergic beta-Agonists; D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004562:Electrocardiography / Q000187:drug effects; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007545:Isoproterenol; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D051381:Rats
C103881:18-dehydroglycyrrhetic acid; D000318:Adrenergic beta-Agonists; D002317:Cardiovascular Agents; D007545:Isoproterenol; D006034:Glycyrrhetinic Acid